For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue | 0 | 0 | 53,811 | 3,181 |
| Research and development | 33,534 | 32,101 | 30,815 | 32,807 |
| General and administrative | 15,235 | 9,763 | 8,924 | 11,341 |
| Total operating expenses | 48,769 | 41,864 | 39,739 | 44,148 |
| Loss from operations | -48,769 | -41,864 | 14,072 | -40,967 |
| Interest income | 2,177 | 1,680 | 1,097 | 1,239 |
| Other income, net | 1,079 | 1,380 | 705 | 910 |
| Total other income, net | 3,256 | 3,060 | 1,802 | 2,149 |
| Loss before income taxes | -45,513 | -38,804 | 15,874 | -38,818 |
| Provision for income taxes | 1 | -55 | -10 | 35 |
| Net loss | -45,514 | -38,749 | 15,884 | -38,853 |
| Unrealized (gain) loss on marketable securities | - | 130 | - | -100 |
| Comprehensive gain | - | -38,619 | - | -38,953 |
| Basic EPS | -0.32 | -0.291 | 0.14 | -0.35 |
| Diluted EPS | -0.32 | -0.306 | 0.13 | -0.35 |
| Basic Average Shares | 143,576,292 | 132,856,311 | 110,966,345 | 110,540,836 |
| Diluted Average Shares | 143,576,292 | 126,040,582 | 117,782,074 | 110,540,836 |
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX)